Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/bc/a2/7d/bca27df8-dee4-a334-b87d-a14647c78c66/mza_9082093750272783927.jpg/600x600bb.jpg
EUCOPE's Sounds of Science
EUCOPE
19 episodes
3 days ago
Helping you get acquainted with the most pressing EU policy files on pharmaceuticals and biotechnologies. Brought to you by EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
Show more...
Life Sciences
Science
RSS
All content for EUCOPE's Sounds of Science is the property of EUCOPE and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Helping you get acquainted with the most pressing EU policy files on pharmaceuticals and biotechnologies. Brought to you by EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/14132187/14132187-1644244028363-74ebd23e62ee8.jpg
Advanced Therapy Medicinal Products (ATMPs): How they will be affected by the General Pharmaceutical Legislation
EUCOPE's Sounds of Science
38 minutes 37 seconds
3 years ago
Advanced Therapy Medicinal Products (ATMPs): How they will be affected by the General Pharmaceutical Legislation

SOUNDS OF SCIENCE - EPISODE 9

On today’s episode, we will be exploring the topic of Advanced Therapy Medical Products, or ATMPs. This covers a wide range of therapies, but we’ll be using it as shorthand for gene and cell therapies for today’s conversation.

ATMPs have been receiving significantly more attention in recent years as a growing number of them come to market. As a potentially one-off, transformative treatment, these therapies are different from many therapies currently available or in development. However, much like all other therapies, ATMPs will be impacted by the ongoing review of the General Pharmaceutical Legislation, and many cases, the review of the OMP regulation as well. Beyond the legislative and regulatory framework, interesting developments are also taking place with regard to HTA and P&R. This combination of commercial and legislative developments will have long-term implications on ATMPs and the competitiveness of the EU.

Suffice to say, there is a lot happening when it comes to ATMPs, and with the help of today’s guests, we hope we can start to unpack a few of these discussions, and possibly look into the future as well.

Today's guests are:

  • Dr Lutz Bonacker, Senior Vice President and General Manager, Commercial Operations Europe, CSL Behring
  • Dr Alexander Natz, Secretary General, EUCOPE

------------------

For more information about our work on ATMPs or how to join our Cell & Gene Therapy Working Group, simply visit our website or send an email to maertens@eucope.org.


EUCOPE's Sounds of Science
Helping you get acquainted with the most pressing EU policy files on pharmaceuticals and biotechnologies. Brought to you by EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.